Related Experiment Video
Updated: Jul 4, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Molecular characterization of CYP2B6 substrates.
Sean Ekins1, Manisha Iyer, Matthew D Krasowski
1Collaborations in Chemistry, 601 Runnymede Ave, Jenkintown, PA 19046. USA. ekinssean@yahoo.com
Current Drug Metabolism
|June 10, 2008
Summary
This study identifies key molecular features of CYP2B6 substrates, revealing they are typically small, hydrophobic molecules, often active in the central nervous system. These findings aid in understanding drug metabolism and discovery.
Area of Science:
- Pharmacology and Toxicology
- Medicinal Chemistry
- Drug Metabolism
Background:
- Cytochrome P450 2B6 (CYP2B6) is crucial for drug metabolism but less understood molecularly than other P450 enzymes.
- Increased availability of in vitro probes has expanded the known substrate pool for CYP2B6.
- Understanding CYP2B6 substrate characteristics is vital for drug development and predicting drug-drug interactions.
Purpose of the Study:
- To determine the molecular features that define CYP2B6 substrates.
- To develop predictive models for identifying potential CYP2B6 substrates.
- To provide insights for drug discovery research involving CYP2B6.
Main Methods:
- Analysis of kinetic data from human recombinant CYP2B6 across multiple laboratories.
- Calculation of molecular properties using the ChemSpider database.
- Application of 2D and 3D Quantitative Structure-Activity Relationship (QSAR) methods for pharmacophore and model generation.
Main Results:
- Identified key molecular properties for CYP2B6 substrates including molecular weight, lipophilicity (ACD/logP, LogD), hydrogen bond donor/acceptor counts, rotatable bonds, and polar surface area.
- Found CYP2B6 substrates to be generally small, hydrophobic molecules.
- Observed a frequent association of CYP2B6 substrates with central nervous system activity.
Conclusions:
- CYP2B6 substrates possess specific molecular characteristics that can be predicted.
- The identified features and predictive models can inform the design of new drugs targeting or metabolized by CYP2B6.
- Findings are significant for optimizing drug discovery and development processes.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...